Underweight CL with defined-risk short overlay: trim to 65–70% benchmark, retain carry structure through catalysts
Underweight is the correct call over both Sell and Hold. Reject full Sell because (1) 8/21 reflection is binding — Underweight at $89.58 forfeited +1.9% alpha when CL rallied off the lower Bollinger, (2) gross margins have expanded 200 bps (59.4% to 61.5%) over four quarters undercutting the bear narrative, and (3) franchise carry is intact (Dividend King, $3.46B FCF covering $3.11B capital return, AAA credit, 200+ country distribution). Reject Hold because 8/24 and 8/26 reflections show bare Hold on broken momentum near multi-indicator resistance reliably leaks −1.6% to −1.9% alpha; current setup is worse (MACD most negative in visible window, RSI 37.72 with room to fall, price below 10 EMA/50 SMA/declining 30-day VWAP simultaneously). The trader's defined-risk short as overlay (not full expression) is retained: the 1.3:1 R/R at current levels does not justify full Underweight sizing in a single entry, and the 9/8 lesson (identical signal cluster at $88.77 produced −0.4% move / +0.0% alpha) is dispositive on magnitude. Three catalyst events converge in the six-week window: September 21 OEF rebalance (mechanical supply event), late October Q3 2026 earnings (margin test vs Q2's pre-shock hedging base), and WTI/DXY sensitivity (dollar strength undermines dividend-yield-rotation thesis for ~60% non-US revenue base). The 50/50 capital deployment into short-duration Treasuries and cash locks carry advantage without rotating into stretched AI-infrastructure beta at their own elevated multiples.
| Position | Action |
|---|---|
| Full position | Trim to 65–70% of benchmark weight (30–35% reduction) |
| Proceeds from trim | Deploy 50/50 between short-duration Treasuries (~250bps yield pickup) and cash for redeployment optionality |
| Tactical short overlay (not full position) | Size at 1–2% of portfolio risk budget; express via three-tranche scaling |
CL at $88.03 testing its 200-day SMA at $87.05 with momentum indicators at extremes and strengthening fundamentals represents a generational defensive entry point with asymmetric upside reward/risk that demands leaning in, not standing pat.
| Indicator | Value | Signal |
|---|---|---|
| Price Close | 88.03 | bearish |
| Price Open | 87.95 | neutral |
| Price High | 88.44 | neutral |
| Price Low | 87.30 | neutral |
| Volume | 4,819,200 | neutral |
| 10 EMA | 89.57 | bearish |
| 50 SMA | 91.53 | bearish |
| 200 SMA | 87.05 | neutral |
| RSI | 37.72 | bearish |
| MACD Line | -0.78 | bearish |
| MACD Signal | -0.45 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Failed retest of broken 200 SMA from below — price retests $87.05 and prints bearish rejection candle
Then: Scale in second quarter of short; stop $87.80–$88.00
↩ rebuts: “The technical setup is broken — MACD is deeply negative”
EV: +$4–7 per share (from $88 entry to $92–95+ targets) · concedes: Trailing valuation looks stretched near 52-week highs (but 200 SMA test changes the setup); Fundamentals report flagged near 52-week high concerns
CL is a SELL because it faces an accelerating downtrend with negative momentum, imminent mechanical selling from S&P 100 OEF removal in 11 days, peak gross margins before PPI re-acceleration, and fully priced valuation at 21.4x forward P/E for below-average growth—creating inverted risk/reward with uncapped downside to $74.55 versus capped upside to ~$95.
· concedes: If CL bounces from $87.05 to $95+, the bear loses the entry point but avoids a potential $13 downside by waiting for better risk/reward; If CL chops sideways for 3 months at $87-90, the bear loses time and opportunity cost; Doing nothing has zero cost, but waiting also has opportunity cost in a market with alternative opportunities
→ vs conservative: Defensive metrics (0.32 beta, 2.41% dividend yield, $3.46B FCF) are irrelevant in a six-week trading window; beta doesn't protect against momentum breakdowns and near-term catalysts
→ vs conservative: RBC Q1 2027 stabilization thesis requires waiting six months, paying 21.4x forward multiple, and absorbing near-term earnings risk—this is hope, not strategy
→ vs conservative: Ignores OEF index removal catalyst on September 21 and Dyson's $499 premium toothbrush launch into CL's most defensible category
→ vs conservative: Anchoring on business quality while ignoring price is value-destructive in a bearish momentum setup
→ vs neutral: Own data confirms MACD accelerating negative, downtrend intact, and 50 SMA rolling toward potential death cross—yet recommendation is to wait for a predicted breakdown
→ vs neutral: Waiting for confirmed $87 breakdown likely means entry at $85 or $84, degrading risk-reward by 30-40%
→ vs neutral: Acknowledges OEF removal catalyst but takes no action; reactive trading disguised as discipline throws away asymmetric opportunity
→ vs neutral: Plan leaves trader waiting for worse entry rather than positioning ahead of high-probability move
| MACD Histogram | -0.33 | bearish |
| Bollinger Middle (20 SMA) | 90.65 | bearish |
| Bollinger Upper Band | 93.39 | neutral |
| Bollinger Lower Band | 87.91 | neutral |
| ATR | 1.69 | neutral |
Support: 87.05 · 87.91 | Resistance: 89.57 · 91.53
The technical analysis reveals a clear short-term bearish trend following a multi-month topping pattern. The stock has broken below its 50-day SMA and is now testing the critical 200-day SMA support zone at 87.05. RSI at 37.72 approaches oversold territory while MACD remains deeply negative with histogram at -0.33, indicating accelerating downside momentum. The convergence of 200 SMA (87.05) and Bollinger Lower Band (87.91) creates a critical support zone. Recommendation is HOLD with watch for capitulation signals near 200 SMA or a decisive breakdown below $87.00.
Market Capitalization
$70.07B
P/E (TTM)
34.61x
Forward P/E
21.40x
PEG Ratio
1.62
P/B
296.96x
Dividend Yield
2.41%
Beta
0.32
52-Week High
$99.33
52-Week Low
$74.55
200-Day MA
~$87.80
Q2'26 Revenue
5,361
Q2'26 Gross Profit
3,296
Q2'26 Operating Income
1,016
Q2'26 Net Income
693
Q2'26 Diluted EPS
$0.86
Q2'26 Gross Margin
61.5%
Q1'26 Revenue
5,324
Q1'26 Net Income
646
Q1'26 Diluted EPS
$0.80
Q4'25 Revenue
5,230
Q4'25 Operating Income
92
Q4'25 Net Income
(37)
Q4'25 Diluted EPS
$(0.05)
Q3'25 Revenue
5,131
Q3'25 Net Income
735
Q3'25 Diluted EPS
$0.91
Q2'25 Revenue
5,110
Q2'25 Net Income
743
Q2'25 Diluted EPS
$0.91
Q4'25 Impairment Charge
~$866M
Underlying Q4'25 Operating Income
~$1.02B
Q2'26 Revenue Growth Y/Y
+4.9%
Q2'26 Revenue Growth Q/Q
+1.8%
Total Assets
$16.79B
Total Debt
$7.857B
Net Debt
$6.487B
Cash & Equivalents
$1.37B
Stockholders' Equity
$0.236B
Treasury Stock
$28.93B
Retained Earnings
$27.09B
Current Ratio
1.03
Goodwill
$3.10B
Q2'26 Operating Cash Flow
995
Q2'26 CapEx
128
Q2'26 Free Cash Flow
867
Q2'26 Dividends Paid
462
Q2'26 Buybacks
291
TTM Free Cash Flow
$3.46B
TTM FCF/Share
~$4.30
Annual Buyback Pace
~$1.2B
Annual Dividend
~$1.85B
Diluted Share Count Q2'25
813.3M
Diluted Share Count Q2'26
801.8M
Share Count Reduction
~1.4%
Operating Margin (TTM)
21.0%
Net Margin (TTM)
9.7%
ROA
15.8%
ROE
2,673%
EBITDA (TTM)
$4.98B
Tax Rate
~24%
Debt Reduction YoY
$900M
Net Debt Reduction YoY
~$1.06B
Working Capital Q2'26
+160M
FCF Dividend Coverage
1.9x
Payout Ratio
~52%
Interest Rate Impact
~5-10bps Y/Y
Business Quality Grade
A
Valuation Grade
C+
Risk/Reward Grade
B-
TTM Revenue
$21.05B
Strengths
Concerns
Colgate-Palmolive is a high-quality consumer staples company with iconic brands (Colgate, Palmolive, Hill's Science Diet) trading at a premium valuation (34.6x P/E TTM, 21.4x forward P/E) near 52-week highs, which limits short-term upside. The company demonstrates strong fundamentals with $3.46B TTM free cash flow, expanding gross margins (61.5%), five consecutive quarters of revenue growth (+4.9% Y/Y), and an aggressive capital return policy returning ~$3B annually to shareholders via dividends and buybacks, though the tight current ratio of 1.03 and elevated debt load present mild liquidity risks for this defensive, low-beta (0.32) stock.
Macro: Markets pricing 93% probability of zero Fed rate cuts in 2026 (Polymarket, $8.2M volume) versus just 8% US recession odds by year-end; PPI re-accelerating signals margin pressure; energy markets tightening from OPEC+ production pause and Iran geopolitical risks; ECB diverging with rate hike to 2.5% adding FX volatility; Easing conditions versus high-rate regime creates mixed signals for consumer staples.